3.1
Zilucoplan (Zilbrysq, UCB Pharma) is indicated 'as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive'.
Closed for comments This consultation ended on at Request commenting lead permission
Zilucoplan (Zilbrysq, UCB Pharma) is indicated 'as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive'.
The dosage schedule is available in the summary of product characteristics for zilucoplan.
The list price of zilucoplan is £3,653.97 for 7 pre-filled syringes of 16.6 mg solution for injection, £5,041.78 for 7 pre-filled syringes of 23.0 mg solution for injection, and £7,114.70 for 7 pre-filled syringes of 32.4 mg solution for injection (all excluding VAT, BNF online, accessed June 2024).
How are you taking part in this consultation?
You will not be able to change how you comment later.
You must be signed in to answer questions
Question on Consultation
Question on Consultation
Question on Consultation
Question on Consultation